On the association of elevated tPA/PAI-1 complex and von willebrand factor with recurrent myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 8, 2000, Pages 1857-1859

  Bounameaux, H ^a   Kruithof, E K O ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Coronary heart disease; Editorials; Inflammation; Myocardial infarction recurrence; Risk factors

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; DISEASE MARKER; EDITORIAL; HEART INFARCTION; HEART REINFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; VASCULAR ENDOTHELIUM;

EID: 0033903229     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.8.1857     Document Type: Editorial

References (23)

1. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
2. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries
3. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
4. Prospective study of endogenous tissue plasminogen activator and risk of myocardial infarction
5. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
6. Tissue plasminogen activator (t-PA) antigen in plasma: Correlation with different tPA/inhibitor complexes
7. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and yon Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm heart epidemiology program (SHEEP) study
8. Association of fibrinogen, factor VII and PAI-I with baseline findings among 10,500 male participants in a prospective study of myocardial infarction: The PRIME Study
9. Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells
10. Targeting of a heterologous protein to a regulated secretion pathway in cultured endothelial cells
11. The Weibel-Palade body: The storage granule for yon Willebrand factor and P-selectin
12. Involvement of calcium and G proteins in the acute release of tissue-type plasminogen activator and yon Willebrand factor from cultured human endothelial cells
13. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo
14. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation: Effect of interleukin 6
15. Acute yon Willebrand factor secretion from the endothelium in vivo: Assessment through plasma propeptide (vWf:AgII) Levels
16. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Cultured human endothelial cells: Modulation by thrombin, endotoxin, and histamine
17. Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms
18. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
19. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
20. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human intefieukin-6 in baboons
21. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: Induction by tumor necrosis factor-α and lipopolysacchafide
22. The effect of ABO blood group on the diagnosis of von Willebrand disease
23. von Willebrand factor (vWF) as a plasma marker of endothelial activation in diabetes: Improved reliability with parallel determination of the vWF propeptide (vWf:AgII)